LSL Pharma Group Inc. (TSXV:LSL)
Canada · Delayed Price · Currency is CAD 0.3200
-0.0100 (-3.03%)
At close: Aug 28, 2026
LSL Pharma Group Revenue
LSL Pharma Group had revenue of 14.63M CAD in the quarter ending June 30, 2026, with 102.66% growth. This brings the company's revenue in the last twelve months to 41.83M, up 80.01% year-over-year. In the year 2025, LSL Pharma Group had annual revenue of 28.74M with 61.96% growth.
Revenue (ttm)
41.83M
Revenue Growth
+80.01%
P/S Ratio
0.97
Revenue / Employee
165.99K
Employees
252
Market Cap
40.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.74M | 11.00M | 61.96% |
| Dec 31, 2024 | 17.75M | 7.72M | 76.98% |
| Dec 31, 2023 | 10.03M | 1.81M | 22.08% |
| Dec 31, 2022 | 8.21M | -557.15K | -6.35% |
| Dec 31, 2021 | 8.77M | -1.28M | -12.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 3, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| iAnthus Capital Holdings | 197.59M |
| Planet 13 Holdings | 131.28M |
| 1CM Inc. | 75.45M |
| Vext Science | 71.97M |
| Rubicon Organics | 64.23M |
| MediPharm Labs | 41.46M |
| Medicure | 32.08M |
| ZYUS Life Sciences | 374.00K |